The second quarter of 2025 was a period of dynamic evolution within the biotech and pharma sectors. Critical factors like ...

The European Commission has approved EZMEKLY (mirdametinib) for treatment of symptomatic, inoperable plexiform neurofibromas ...

The European Commission (EC) has granted conditional approval to SpringWorks Therapeutics’ Ezmekly (mirdametinib) to treat ...

The European Commission granted conditional marketing authorization for Ezmekly (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients ...

Merck KGaA (NYSE:MRK) said that the European Commission approved Ezmekly for treating symptomatic, inoperable plexiform ...

Merck KGaA said its Ezmekly therapy for people with a rare genetic disorder has received the conditional marketing approval from the European Commission. The pharmaceutical company said Friday that ...

EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) ...

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted conditional marketing authorization ...

NORTHAMPTON, MA / ACCESS Newswire / July 17, 2025 / "Sustainability for sustainability's sake doesn't often work. We have found a lot of ways to connect it to the business and business value."This is ...

Just over two years into Anderson's tenure, Bayer's board has decided to extend his contract by three years to 31st March ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

Merck KGaA, Darmstadt, Germany recently invited leading representatives from the semiconductor industry to Darmstadt to come together and discuss the role of Germany and Europe in this global industry ...